Onco Actu du 1er juin 2016

	2.4 Etiologie - Portables, ondes e-m
NTP and Brain Tumor Rates [Microwave News] The issue of whether brain tumor rates are static or rising is more complicated than Kolata would have us believe. It’s true that the overall incidence of brain tumors has not been changing much, but a different picture emerges if one looks, carefully, at the data.
The New Health Care: Why It’s Not Time to Panic About Cellphones and Cancer [NY Times] If you want to own the positive result seen in males, you have to own the protection being female seems to confer. You have to own that the control rats were somehow magically without cancer. You have to own that cellphone exposure increases life span. Or you can admit that none of these results are especially convincing.
	2.6 Etiologie - Environnement
EU set to consider temporary extension of glyphosate license over cancer row [Reuters] The proposal will be put to a vote by experts from the 28 EU nations on Monday.
	3.1 Tabac
Linda Bauld: The road to standardised tobacco packaging in the UK [BMJ Blogs] We now need to turn our attention to evaluating the impact of this change. These evaluation results could inform efforts in other countries to remove branded tobacco packaging—the “silent salesman” of a uniquely deadly product.
World No Tobacco Day 2016: how plain packs are helping Australia’s record-low smoking rates [Cancer Research UK] In 2012, Australia became the first country in the world to introduce standard packs. And in this post, Kylie Lindorff, from the Cancer Council Victoria, tells us more about the Australian experience of binning this shocking form of marketing.
Cigarette plain packs to 'go global' [BBC News] The Tobacco Manufacturers' Association said policy was being "driven more by dogma than hard fact".
White House scrapped FDA plan to restrict flavored e-cigarettes [Reuters] A White House office deleted language in a recently introduced tobacco regulation that would have removed flavored e-cigarettes from the market until they had been authorized by the Food and Drug Administration, an edited version of the document shows.
	5. Traitements
Treatment 'breakthrough' in man with advanced skin cancer [NHS Choices] These are promising findings, but are also the results of just one case. Ten people received the same treatment combination as the man, but only he and one other achieved the same remission.
Statins 'could be valuable addition to breast cancer treatment' [The Guardian] The research has not yet been tested in humans. The scientists grew cancer cells in the lab in the absence of oestrogen and found they produced an alternative fuel, in the form of the cholesterol molecule. They then interfered with production of the molecule and found it slowed the cancer cells’ growth by between 30% and 50%.
	5.2 Pharma
Daiichi Sankyo to not proceed with lung cancer study [Reuters] Daiichi Sankyo Co Ltd said it will not proceed with the second part of its late-stage study on the lung cancer drug, patritumab. This decision on Tuesday followed the recommendation of an independent data monitoring committee that concluded the first part of the study did not meet the required efficacy criteria.
	5.2.1 Pharma - Partenariats
Bayer collaborates with U.S. National Surgical Adjuvant Breast and Bowel Project (NSABP) to Investigate Stivarga® (Regorafenib) as Additional Adjuvant Therapy in Colon Cancer [Bayer] Study will include patients with Stage IIIB and IIIC colon cancer who have undergone complete surgical resection of primary tumor and received standard adjuvant chemotherapy / Indication-seeking trial will be conducted by NSABP with the support from Bayer.
	5.2.2 Pharma - Fusions & Acquisitions
Celator Gets Bought, As Stock Rockets From $1.68 To $30.25 In Two Months [Forbes] The acquisition of Celator comes on the eve of the American Society of Clinical Oncology meeting, the biggest annual gathering of cancer researchers and drugmakers. Detailed results are scheduled to be presented on Saturday at the conference.
Celator Parlays Leukemia Drug Data into $1.5B Buyout From Jazz Pharma [Xconomy] Celator was to file for approval of CPX-351, known as Vyxeos, in the U.S. and Europe later this year. But developing a drug is completely different from successfully launching and selling it, and the latter is often best suited for companies with those capabilities already in place.
	5.2.3 Pharma - économie
Genmab bags $30M milestone from J&J as Darzalex money machine fires up [FierceBiotech] Darzalex, which during development was known as daratumumab, racked up the sale days after the European Commission gave the green light to the drug.
	5.3 Traitements - FDA, EMA,...
Regulatory information - A new operating model for procedure management to improve support for evaluation procedures [EMA] Change will optimise support on regulatory procedural aspects.
	5.3.4 Traitements - AMM (FDA, EMA)
EC approves ibrutinib for patients with newly diagnosed CLL [European Pharmaceutical Review] This latest EC approval follows the decision by the US Food and Drug Administration in March to approve the expanded use of ibrutinib capsules for treatment-naïve patients with CLL.
	5.4 Traitements - Economie
Nice rejects Janssen's Imbruvica in draft guidance [Pharmafile] The National Institute for Health and Care Excellence (Nice) said although its advisory committee felt Imbruvica could benefit patients it recognised that with the current proposal, the drug was not cost effective.
Money-back guarantee: the new trend in drug and device marketing [STAT] Some of the pharmaceutical and medical device executives I talk to have a “this too shall pass” mentality. They’ve been through the wringer before and hold onto the hope that today’s headlines will fade and the media will find new dragons to slay tomorrow.
	5.5 ASCO
Vice President Biden to Discuss National Cancer Moonshot Initiative at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting [ASCO] “The Moonshot Initiative can be a vehicle for major new progress against cancer, and ASCO's Annual Meeting will address practically all of its essential elements.”
Five Storylines To Watch At ASCO [Forbes] Let’s hope for more healthy skepticism from all parties at this year’s ASCO.
	5.5.4 ASCO (immunothérapies)
Kite Pharma to Highlight Key Data from Engineered CAR T Cell Therapy Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting [Kite] Data to be presented include results from Kite's SCHOLAR-1 study, the first and largest meta-analysis of outcomes in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL), an aggressive non-Hodgkin lymphoma (NHL).
	6. Lutte contre les cancers
University of Maryland Cancer Center Earns Comprehensive Designation [The Cancer Letter] On Aug. 1, when the designation goes in effect, Maryland will become one of the 46 Comprehensive Cancer Centers in the U.S.
	6.1 Observation
American Death Rate Rises for First Time in a Decade [NY Times] “Many countries in Europe are witnessing declines in mortality, so the gap between the U.S. and other countries is growing.”
	6.10 Politiques
After meeting Nobel laureates, French president backs off ‘suicidal’ science cuts [Science] Haroche says Hollande also promised his visitors that he'll try to free up more money for research and for France's universities in the government's next annual budget.
	6.11 Patients
At Stanford’s new cancer center, patients interview every new hire [Quartz] Abbott said patients ask completely different questions of prospective staff and have provided crucial perspective for the center to carry out its mission to be patient-centric.
	6.5 Médecines alternatives
He’s 20. Has brain cancer. And is caught in the crossfire between the FDA and a renegade doctor [STAT] Neil and his family grew excited about an experimental therapy offered by a renegade Texas physician, Dr. Stanislaw Burzynski, and he flew to Houston to get infusions — but got them for just for a single day before federal regulators abruptly ordered the treatments to stop.
	6.6 Publications
Why Sci-Hub Will Win [Medium] Basically, massive academic publishers need to change or die, because a system for instantly disseminating research that’s built out of driftwood and thumbtacks has sprung up, and the big news is not that it’s free, it’s that it’s better.
Elsevier is tricking authors into surrendering their rights [it is NOT junk] To put it simply, Elsevier have distorted the widely recognized concept of open access, in which authors retain copyright in their work and give others permission to reuse it, and where publishers are a vehicle authors use to distribute their work, into “Elsevier access” in which Elsevier, and not authors, retain all rights not granted by the license.